Five things to know:
- The treatment, named AZD7442, is a combination of tixagevimab and cilgavimab.
- Participants who received 600 milligrams of AZD7442 were 50 percent less likely to develop severe COVID-19 or die from any cause compared to the placebo group.
- The trial participants had been symptomatic for seven days or fewer and were randomized 1:1 when split into the AZD7442 and placebo arms. Ninety percent of participants were from populations at high risk of progressing to severe COVID-19.
- In August, AstraZeneca said AZD7442 was 77 percent effective in preventing symptomatic COVID-19 during a 5,197-participant trial. On Oct. 5, the drugmaker filed for FDA emergency use authorization for the antibody cocktail’s use as a preventive treatment of symptomatic COVID-19.
- If authorized, AZD7442 would be the first antibody drug cleared for COVID-19 prevention.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
